Clinical Trial Update: A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study of MGCD0103 in combination with gemcitabine has completed; the update provides trial status without detailing results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• MGCD0103 (MG-0103) (MGCD0103)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Tumors | Phase 1, Phase 2 | Status: COMPLETED